Christoph C Carter

2.2k total citations · 2 hit papers
24 papers, 780 citations indexed

About

Christoph C Carter is a scholar working on Infectious Diseases, Emergency Medicine and Virology. According to data from OpenAlex, Christoph C Carter has authored 24 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 8 papers in Emergency Medicine and 6 papers in Virology. Recurrent topics in Christoph C Carter's work include HIV/AIDS Research and Interventions (15 papers), HIV/AIDS drug development and treatment (14 papers) and HIV-related health complications and treatments (8 papers). Christoph C Carter is often cited by papers focused on HIV/AIDS Research and Interventions (15 papers), HIV/AIDS drug development and treatment (14 papers) and HIV-related health complications and treatments (8 papers). Christoph C Carter collaborates with scholars based in United States, Germany and France. Christoph C Carter's co-authors include Moupali Das, Jordan E. Lake, Grace A. McComsey, John R. Koethe, Jürgen K. Rockstroh, Kristine M. Erlandson, Stefan Eßer, Frank A. Post, Laura Waters and Paul E. Sax and has published in prestigious journals such as The Lancet, JAMA and PLoS ONE.

In The Last Decade

Christoph C Carter

22 papers receiving 774 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

2019 468 citations Paul E. Sax, Kristine M. Erlandson et al. Clinical Infectious Diseases profile →
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study

2025 14 citations John Ling, Anna Chiu et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christoph C Carter United States	11	532	478	257	127	70	24	780
María Luisa Navarro Spain	15	335 0.6×	213 0.4×	197 0.8×	130 1.0×	44 0.6×	61	574
María Isabel de José Spain	16	407 0.8×	278 0.6×	250 1.0×	220 1.7×	20 0.3×	47	661
Simona Di Giambenedetto Italy	15	424 0.8×	252 0.5×	341 1.3×	248 2.0×	49 0.7×	66	719
Dan Ouchi Spain	15	425 0.8×	73 0.2×	342 1.3×	149 1.2×	78 1.1×	50	781
Hadewych J. M. ter Hofstede Netherlands	9	732 1.4×	404 0.8×	367 1.4×	241 1.9×	103 1.5×	15	1.0k
M. A. Sambeat Spain	17	496 0.9×	354 0.7×	422 1.6×	295 2.3×	108 1.5×	24	879
Evangelo Boumis Italy	14	276 0.5×	78 0.2×	139 0.5×	244 1.9×	58 0.8×	35	571
Jan Vesterbacka Sweden	11	268 0.5×	170 0.4×	195 0.8×	63 0.5×	247 3.5×	25	495
Pierfrancesco Grima Italy	15	234 0.4×	183 0.4×	193 0.8×	178 1.4×	20 0.3×	46	575
Opass Putcharoen Thailand	13	429 0.8×	49 0.1×	100 0.4×	119 0.9×	41 0.6×	47	546

Countries citing papers authored by Christoph C Carter

Since Specialization

Citations

This map shows the geographic impact of Christoph C Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph C Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph C Carter more than expected).

Fields of papers citing papers by Christoph C Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph C Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph C Carter. The network helps show where Christoph C Carter may publish in the future.

Co-authorship network of co-authors of Christoph C Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph C Carter. A scholar is included among the top collaborators of Christoph C Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph C Carter. Christoph C Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cox, Stephanie, Kristen Andreatta, Matthew R. Hendricks, et al.. (2025). Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. The Journal of Infectious Diseases. 233(1). e203–e211.

Ling, John, et al.. (2025). Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. The Lancet. 405(10485). 1147–1154. 14 indexed citations breakdown →

Marrazzo, Jeanne, Tao Li, Marissa Becker, et al.. (2024). HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. JAMA. 331(11). 930–930. 31 indexed citations

Li, Tao, J. Carlo Hojilla, Juan Yang, et al.. (2023). 1556. Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) During the COVID-19 Pandemic. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Cespedes, Michelle, Moupali Das, Maria Prins, et al.. (2022). Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial. Transgender Health. 9(1). 46–52. 10 indexed citations

Cespedes, Michelle, Moupali Das, J. Carlo Hojilla, et al.. (2022). Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS ONE. 17(6). e0267780–e0267780. 23 indexed citations

Cox, Stephanie, Alexander Kintu, Flavia Matovu Kiweewa, et al.. (2022). 2079. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda. Open Forum Infectious Diseases. 9(Supplement_2). 1 indexed citations

Cespedes, Michelle, Jill Blumenthal, Karam Mounzer, et al.. (2021). 848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial. Open Forum Infectious Diseases. 8(Supplement_1). S514–S514. 1 indexed citations

Li, Tao, et al.. (2020). 103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence. Open Forum Infectious Diseases. 7(Supplement_1). S181–S181.

10.

Eron, Joseph J., Aimee Wilkin, Moti Ramgopal, et al.. (2020). 1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis. Open Forum Infectious Diseases. 7(Supplement_1). S529–S530. 6 indexed citations

11.

Campbell, Thomas, Amanda Clarke, Benoît Trottier, et al.. (2020). 995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline. Open Forum Infectious Diseases. 7(Supplement_1). S526–S527. 2 indexed citations

12.

Trevaskis, James L., Christoph C Carter, Kirsten White, et al.. (2020). Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS ONE. 15(2). e0229617–e0229617. 32 indexed citations

13.

Daar, Eric S., Jason Brunetta, Éric Cua, et al.. (2020). 985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial. Open Forum Infectious Diseases. 7(Supplement_1). S521–S521. 1 indexed citations

14.

Regier, Mary C., Christoph C Carter, John D. Aitchison, et al.. (2019). Spatial presentation of biological molecules to cells by localized diffusive transfer. Lab on a Chip. 19(12). 2114–2126. 1 indexed citations

15.

Eron, Joseph J., Jean‐Daniel Lelièvre, Robert C. Kalayjian, et al.. (2019). 2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis. Open Forum Infectious Diseases. 6(Supplement_2). S864–S864. 4 indexed citations

16.

Sax, Paul E., Kristine M. Erlandson, Jordan E. Lake, et al.. (2019). Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clinical Infectious Diseases. 71(6). 1379–1389. 468 indexed citations breakdown →

17.

Mills, Anthony, Kimberly Workowski, Thomas Campbell, et al.. (2019). 1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial. Open Forum Infectious Diseases. 6(Supplement_2). S64–S64. 4 indexed citations

18.

Carter, Christoph C, Kevan Akrami, Drew A. Hall, Davey M. Smith, & Eliah Aronoff‐Spencer. (2017). Lyophilized visually readable loop-mediated isothermal reverse transcriptase nucleic acid amplification test for detection Ebola Zaire RNA. Journal of Virological Methods. 244. 32–38. 47 indexed citations

19.

Carter, Christoph C, Gabriel A. Wagner, George K. Hightower, et al.. (2014). HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing. Virology. 474. 34–40. 19 indexed citations

20.

Carter, Christoph C, Reza Izadpanah, & Eileen Bridge. (2003). Evaluating the role of CRM1-mediated export for adenovirus gene expression. Virology. 315(1). 224–233. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact